Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Phase 1b/2a Trial to Evaluate LEP-F1 + GLA-SE in Healthy Adults and Leprosy Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03947437
Recruitment Status : Not yet recruiting
First Posted : May 13, 2019
Last Update Posted : September 16, 2021
Oswaldo Cruz Institute
Information provided by (Responsible Party):
The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)

Brief Summary:
This is a phase 1b/2a, double-blind, randomized, placebo-controlled clinical trial to evaluate the safety, tolerability, and immunogenicity of the LEP-F1 + GLA-SE investigational vaccine compared to placebo.

Condition or disease Intervention/treatment Phase
Leprosy Biological: LEP-F1 + GLA-SE Biological: Placebo Phase 1 Phase 2

Detailed Description:

The proposed clinical trial will establish an initial safety profile for the vaccine in a region endemic for leprosy. The trial will enroll both healthy participants and paucibacillary leprosy patients receiving standard-of-care therapy. Safety at the lower vaccine dose will be demonstrated in healthy participants prior to antigen dose-escalation. Further, safety in all healthy participants will be demonstrated prior to enrolling leprosy patients.

Participants will be randomized within each Group to receive three doses of vaccine or placebo administered IM on Days 0, 28, and 56. Participants will be monitored for one year following the last study injection.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 54 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Masking Description: Participants, investigators, outcomes assessors, and laboratory personnel performing immunology assays will be blinded to treatment assignment. However, the study product administrators will be unblinded due to a difference in product appearance. These personnel will not be involved in study-related assessments or have participant contact for data collection following study injection.
Primary Purpose: Treatment
Official Title: A Phase 1b / 2a, Double-Blind, Randomized, Placebo-Controlled, Antigen Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of LEP-F1 + GLA-SE in Adult Participants in Areas Endemic for Leprosy
Estimated Study Start Date : January 2022
Estimated Primary Completion Date : April 2022
Estimated Study Completion Date : September 2024

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Leprosy

Arm Intervention/treatment
Experimental: Low dose
2 μg LEP-F1 + 5 μg GLA-SE will be administered by IM injection on Days 0, 28, and 56 in healthy participants.
Biological: LEP-F1 + GLA-SE
Leprosy antigen formulated with an adjuvant.
Other Name: LepVax

Experimental: High dose
10 μg LEP-F1 + 5 μg GLA-SE will be administered by IM injection on Days 0, 28, and 56 in healthy participants.
Biological: LEP-F1 + GLA-SE
Leprosy antigen formulated with an adjuvant.
Other Name: LepVax

Experimental: TBD dose in patients
TBD μg LEP-F1 + 5 μg GLA-SE will be administered by IM injection on Days 0, 28, and 56 in paucibacillary leprosy patients. Dose will be determined by safety and immunogenicity data from healthy participants.
Biological: LEP-F1 + GLA-SE
Leprosy antigen formulated with an adjuvant.
Other Name: LepVax

Placebo Comparator: Placebo
Sterile normal saline for injection will be administered by IM injection on Days 0, 28, and 56 in healthy participants and paucibacillary leprosy patients.
Biological: Placebo
Sterile normal saline for injection.

Primary Outcome Measures :
  1. Number of participants experiencing solicited AEs [ Time Frame: 7 days following each injection ]
  2. Number of participants experiencing unsolicited AEs [ Time Frame: Days 0 to 84 ]
  3. Number of participants experiencing medically-attended adverse events considered related to any of the study injections [ Time Frame: Days 0 to 421 ]

Secondary Outcome Measures :
  1. IgG antibody responses to LEP-F1 by ELISA [ Time Frame: Days 0, 35, and 63 ]
  2. T cell responses measured by selected cytokine production to LEP-F1 by whole blood assay [ Time Frame: Days 0, 35, and 63 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Males and females ≥ 18 years and ≤ 55 years of age.
  2. For Cohort 1, participants must be in good general health as confirmed by a medical history and physical exam. For Cohort 2, patients must have confirmed diagnosis of paucibacillary leprosy.
  3. Female participants of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test on the day of each study vaccination, must not be breast-feeding, and are required to use one of the following methods of contraception from enrollment in study until 30 days after last injection (only if in sexual relationships with men): hormonal (e.g. oral, transdermal, intravaginal, implant, or injection); double barrier (i.e., condom, diaphragm, or cervical cap with spermicide); intrauterine device (IUD) or system (IUS); vasectomized partner (6 months minimum); or abstinence; bilateral tubal ligation (if no conception post-procedure); tubal occlusion; or bilateral salpingectomy. These precautions are necessary due to unknown effects that LEP-F1 + GLA-SE might cause in a fetus or newborn infant. Women are considered non-child-bearing potential if they are post-menopausal (menopause defined as at least 12 months spontaneous amenorrhea) or have had documented hysterectomy and/or oophorectomy.
  4. Screening laboratory values within the normal ranges or not clinically significant as determined by the Investigator and approved by the Medical Monitor: sodium, potassium, ALT, AST, total bilirubin, alkaline phosphatase, creatinine, fasting glucose, total WBC count, hemoglobin, and platelet count. Abnormal results may be repeated once for confirmation at Investigator discretion.
  5. Negative HIV 1/2 antibody, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, and QuantiFERON®-TB Gold (QFT).
  6. Normal or not clinically significant urinalysis as determined by the study clinician or designee. Abnormal results may be repeated at Investigator discretion.
  7. Subject is capable of completing a study memory aid.
  8. Subject gave informed consent, is able and willing to make all evaluation visits, is reachable by telephone or personal contact by the study site personnel, and is willing to remain in the study area for the duration of the trial.

Exclusion Criteria:

  1. For Cohort 1, history of infection with M. leprae.
  2. Previous exposure to M. leprae vaccines or experimental products containing GLA-SE.
  3. History of active or documented latent TB.
  4. History of previous infection with other non-tuberculous mycobacteria.
  5. Participation in another experimental protocol and/or receipt of any investigational products within the past 3 months prior to Enrollment.
  6. Received any vaccine within 30 days prior to Enrollment or plan to have any immunizations between Days 0-63 due to the washout period prior to immunology blood draws.
  7. Received a blood transfusion within 3 months prior to Enrollment.
  8. Donated blood products (platelets, whole blood, plasma, etc.) within 30 days prior to Enrollment.
  9. Treatment with immunosuppressive drugs (e.g., oral or injected steroids, such as prednisone; high dose inhaled steroids) or cytotoxic therapies (e.g., chemotherapy drugs or radiation) in the past 6 months prior to Enrollment.
  10. History of autoimmune disease or other causes of immunosuppressive states.
  11. History of any other acute or chronic illness (including cardiovascular, pulmonary, neurological, hepatic, rheumatic, hematological, metabolic or renal disorders, uncontrolled hypertension), or use of medication that, in the opinion of the Principal Investigator, may interfere with the evaluation of the safety or immunogenicity of the vaccine.
  12. Rash, tattoos, or any other dermatological condition that could adversely affect the vaccine injection site or interfere with its evaluation.
  13. BMI ≥ 32.
  14. Hypertension (systolic > 150 or diastolic > 95).
  15. History of significant psychiatric illness with current use of medication.
  16. Known or suspected alcohol or drug abuse within the past 6 months prior to Screening.
  17. Smokes 1 pack or more of cigarettes per day.
  18. History of previous anaphylaxis or severe allergic reaction to vaccines or unknown allergens.
  19. Participants who are unlikely to cooperate with the requirements of the study protocol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03947437

Layout table for location contacts
Contact: Cassio Porto Ferreira, PhD +552125621588 ext 1588
Contact: Milton Moraes, PhD +552125621573 ext 1573

Layout table for location information
Oswaldo Cruz Institute (Fiocruz)
Rio de Janeiro, Rj, Cep, Brazil, 21040-900
Principal Investigator: Cassio P Ferreira, PHD         
Principal Investigator: Milton O Moraes, PHD         
Sponsors and Collaborators
The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
Oswaldo Cruz Institute
Layout table for investigator information
Principal Investigator: Milton Moraes, PhD Oswaldo Cruz Institute
Layout table for additonal information
Responsible Party: The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) Identifier: NCT03947437    
Other Study ID Numbers: IDRI-LEPVPX-119
First Posted: May 13, 2019    Key Record Dates
Last Update Posted: September 16, 2021
Last Verified: September 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Mycobacterium Infections, Nontuberculous
Mycobacterium Infections
Actinomycetales Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Bacterial Infections and Mycoses